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Background: Serious lower respiratory tract infections (SLRTIs), especially Streptococcus pneumoniae (SP)-related
pneumonia cause considerable morbidity and mortality. Chest imaging, sputum and blood culture are not routinely
obtained by general practitioners (GPs). Antibiotic therapy is usually started empirically. The BinaxNOW® and Urine
Antigen Detection (UAD) assays have been developed respectively to detect a common antigen from all pneumococcal
strains and the 13 pneumococcal serotypes present in the vaccine Prevenar 13® (PCV13).
Methods: OPUS-B was a multicentre, prospective, case-control, observational study of patients with SLRTI in primary
care in Belgium, conducted during two winter seasons (2011–2013). A urine sample was collected at baseline for the
urine assays. GPs were blinded to the results. All patients with a positive BinaxNOW® test and twice as much randomly
selected BinaxNOW® negative patients were followed up. Recorded data included: socio-demographics, medical
history, vaccination history, clinical symptoms, CRB-65 score, treatments, hospitalization, blood cultures, healthcare
use, EQ-5D score. The objectives were to evaluate the percentage of SP SLRTI within the total number of SLRTIs,
to assess the percentage of SP serotypes and to compare the burden of disease between pneumococcal and
non-pneumococcal SLRTIs.
Results: There were 26 patients with a BinaxNOW® positive test and 518 patients with a BinaxNOW® negative
test. The proportion of pneumococcal SLRTI was 4.8 % (95 % CI: 3.1 %–7.2 %). Sixty-eight percent of positive cases
showed serotypes represented in PCV13. In the BinaxNOW-positive patients, women were more numerous, there
was less exposure to young children, seasonal influenza vaccination was less frequent, COPD was more frequent,
the body temperature and the number of breaths per minute were higher, the systolic blood pressure was lower,
the frequency of sputum, infiltrate, chest pain, muscle ache, confusion/disorientation, diarrhoea, pneumonia and
exacerbations of COPD was more frequent, EQ-5D index and VAS scale were lower, the number of visits to the GP, of
working days lost and of days patients needed assistance were higher.
Conclusions: SP was responsible for approximately 5 % of SLRTIs observed in primary care in Belgium. Pneumococcal
infection was associated with a significant increase in morbidity. Sixty-eight percent of serotypes causing SLRTI were
potentially preventable by PCV13.
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Lower respiratory tract infections (LRTIs), and more par-
ticularly community-acquired pneumonia (CAP), cause
considerable morbidity and mortality in adults, espe-
cially in the elderly. In Europe, the overall annual inci-
dence of CAP in adults ranges between 1.07 and 1.20
per 1,000 person-years, 14 per 1,000 person-years in
adults aged ≥65 years and up to 40 per 1,000 person-
years in patients over 80 years [1]. In the USA, pneu-
monia occurs in about 12 persons per 1,000 annually,
and its incidence is highest among persons at the ex-
tremes of the age range. It is the sixth leading cause of
death in the United States [2].
Clinical symptoms alone do not allow the definite
identification of serious LRTI (SLRTI) aetiology. Diag-
nostic procedures such as chest imaging, sputum and
blood culture, recommended by international guidelines
[3, 4], are not routinely obtained in primary care and do
not allow a timely or definite diagnosis. Antibiotic ther-
apy is usually started empirically and targeted to limit
the risk of hospitalization and mortality by pneumococ-
cal pneumonia [2, 5, 6].
Epidemiological surveys demonstrate the importance
of Streptococcus pneumoniae as the primary pathogen in
CAP [7–9]. However, most data on pneumococcal dis-
ease originate from invasive disease in hospitalised pa-
tients. Data in non-hospitalised or ambulatory patients
are very limited. Due to the lack of timely and sensitive
diagnostic tools, the burden of pneumococcal disease in
SLRTIs is underestimated in general practice [10].
According to the British Thoracic Society guidelines
for the management of CAP in adults (update 2009),
pneumococcal urine antigen tests should be performed
for all patients with moderate or high severity CAP. A
rapid testing and reporting service for pneumococcal
urine antigen should be available to all hospitals admitting
patients with CAP [4]. The BinaxNOW® S. pneumoniae is
an easy-to-use, urine-based, immunochromatographic
membrane test, taking around 15 min to obtain the result,
that allows detecting a common antigen from all pneumo-
coccal strains with a sensitivity of 86 % and a specificity of
94 % [11, 12]. A Luminex technology-based multiplex
urinary antigen detection (UAD) has been validated to
identify 13 pneumococcal serotypes (serotypes 1, 3, 4, 5,
6A/C, 6B, 7 F/A, 9 V/A, 14, 18, 19A, 19 F, 23F, all present
in the 13-valent pneumococcal conjugated vaccine
[PCV13] Prevenar 13®). UAD has a sensitivity of 97 % and
a specificity of 100 % [13]. In the recently published
CAPITA trial [14] evaluating the efficacy of PCV13 versus
placebo in adults 65 years of age or older, the UAD assay
allowed to determine a 45.6 % reduction in vaccine-type
CAP.
The proportion of European patients consulting in pri-
mary care with LRTI, which receives antibiotics, rangesfrom 27 % in the Netherlands to 75 % in the United
Kingdom [15, 16]. In the large prospective international
comparative study GRACE, concerning the management
of acute cough among adults in primary care, consider-
able variation in the 13 countries studied was found.
Major differences in the decision whether or not to pre-
scribe an antibiotic in these settings remained, even after
adjustment for clinical presentation (symptoms, duration
of illness, smoking, age, comorbidity, and temperature).
Patients included by a network based in Belgium (Ant-
werp) were at least two times less likely to be prescribed
antibiotics (25 %) than average (53 %) [17]. Prescription
of antibiotics is nevertheless very much needed in SLRTIs
because of possible serious complications and because of
the higher efficiency of antibiotics when prescribed earlier
in the course of the disease.
OPUS-B was a multicentre prospective observational
(non-interventional) study of patients with SLRTI in pri-
mary care in Belgium, conducted during two winter sea-
sons (2011–2013). This study is one of the first studies
that combined BinaxNOW® S. pneumoniae and UAD as-
says for identification of pneumococcal infection in
urine samples. Its primary objectives were to evaluate
the percentage of S. pneumoniae SLRTI within the total
number of SLRTIs and to evaluate the percentage of sero-
type specific S. pneumoniae SLRTI using the serotype spe-
cific UAD. Its secondary objectives were to compare the
burden of disease in terms of healthcare use and loss of
functionality between pneumococcal SLRTI and non-
pneumococcal SLRTI, to describe common practices and
antibiotic use and to estimate the proportion of pneumo-
coccal SLRTI that could be prevented by vaccination with
PCV13.
Methods
The OPUS-B study was a multicentre, prospective, case-
control, observational and epidemiological trial in primary
care. The objective was to enrol 670 patients (see sample
size analysis below) with a SLRTI over two winter seasons
(from end February 2011 till end March 2013).
The study was conducted in accordance with Good
Clinical Practice and the Declaration of Helsinki. An in-
formed consent was obtained from all participants and
the study protocol was approved by the Ethics Commit-
tee of the University Hospital of Leuven. The presence
of a SLRTI was defined by the following criteria: new or
worsening cough AND shortness of breath or wheezing
or chest pain or new auscultation abnormalities AND
rapid variation of temperature: >38.5 °C for patients
≤60 years; >38 °C or <36 °C for patients >60 years AND
general signs including malaise, asthenia, headache, my-
algia, perspiring/sweating, shivers or confusion AND ab-
sence of sore throat and rhinorrhoea. Participation in
Number of patients enrolled N=549 
No urine sample N=1
Total cohort N=548
BinaxNow–positive N=26
BinaxNow–negative N=518
No result N=4
Follow-up cohort N=85
BinaxNow–positive N=25
BinaxNow–negative N=60
No follow-up visit N=461
Consent withdrawal N=1
Other reason N=1
(absence of the investigator  
for personal reasons)
Fig. 1 Study enrollment
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were the two exclusion criteria.
A urine sample was collected at the baseline visit. This
sample was sent to a central laboratory (Institut de Bio-
logie Clinique, Université Libre de Bruxelles, Brussels,
Belgium) for the BinaxNOW assay and for preparation,
storage and shipping to Pfizer Vaccines Research and Early
Development lab, Pearl River, PA, USA, to perform the
UAD assays. General practitioners (GPs) were blinded to
the BinaxNOW results to avoid any influence of the test
on the patient’s further treatment.
All patients with a positive BinaxNOW test and ap-
proximately twice as much randomly selected Binax-
NOW negative (case-control) patients had a follow up
by the GP.
The physician was entirely free to undertake any im-
aging investigations (X-rays) and to treat the patient ac-
cording to his/her own routine practice.
The following data were recorded in all patients using
an electronic case report form: socio-demographics, med-
ical history, vaccination history, clinical symptoms, CRB-
65 score (Confusion, Respiratory rate, Blood pressure
and Age ≥65 years; score 0 [best] to 4 [worst]) [18, 19],
LRTI management including pharmacological and non-
pharmacological treatments, hospitalization, complemen-
tary investigations (including chest X-rays), blood cultures,
healthcare use, productivity assessment and functional
status (EQ-5D index score) (EuroQol, Rotterdam, The
Netherlands, http://www.euroqol.org/; the index score
being determined according to Agency for Healthcare
Research and Quality [20]; the lowest the score the
worse the patient’s health status) including its visual
analogue scale (VAS; 0 = worst health you can imagine
and 100 = best health you can imagine). Clinical signs,
LRTI management, functional status, additional investiga-
tions and productivity assessment were recorded at each
re-consultation up to 4 to 5 weeks after inclusion in the
selected BinaxNOW-positive and -negative patients.
The sample size was not defined on the basis of a pre-
defined hypothesis testing. Taking into account a mid-
point prevalence of pneumococcal CAP of 8.5 % among
all cases of adult SLRTI managed by GPs in the commu-
nity [21], the total number of patients to include into
the study to achieve 50 BinaxNOW-positive cases would
be 588 patients. The sensitivity of the BinaxNOW assay
has been shown to be 86 % meaning that the percentage
of false negative was going to be around 14 %. Therefore,
it was estimated that the number of patients to include
into the study was to be around 670 patients.
IBM-SPSS Statistics (Version 21.0) was used for the
statistical analyses. Missing data were not replaced nor
extrapolated. Classical descriptive statistics were used
throughout the analyses. Main frequencies were accom-
panied by 95 % Clopper-Pearson’s confidence intervals(CIs). Patients with a pneumococcal SLRTI were com-
pared to patients with a non-pneumococcal SLRTI. Con-
tinuous variables were compared between the two
groups of patients using Mann-Whitney’s tests. Discrete
variables were compared between the two groups using
chi square tests, Fisher’s exact tests or Mann-Whitney’s
tests, as appropriate. Taking into account the multiplicity
of comparisons (around 65), a Bonferroni’s correction
was made on the p value which was divided by 65.
Therefore a p-value <0.00075 was considered statistically
significant. P value between 0.00075 and 0.049 were con-
sidered indicative only of a potential difference between
the two groups.
Results
Overall, 549 patients were enrolled into the study by 38
GPs between February 2011 and March 2013. No urine
sample was available for one patient. The total cohort
therefore included 548 patients (26 patients with a
BinaxNOW positive test, 518 patients with a BinaxNOW
negative test and 4 patients for whom the laboratory re-
sult was not available). In the follow-up cohort, there
were 85 patients: 25 patients with a BinaxNOW positive
test (1 patient was lost to follow-up after the baseline as-
sessment) and 60 patients with a BinaxNOW negative
test (Fig. 1).
Table 1 Demographics, medical history, clinical symptoms,
diagnostic tests, treatments and functional status of primary
care patients with a serious lower respiratory tract infection
(N = 548; Total cohort)
Categories Mean ± SD or N (%)
Demographics
Age (year) 54.8 ± 18.1
Age group 18–49 years 208 (38.0)
50–64 years 165 (30.1)
≥65 years 175 (31.9)
Gender Male 254 (46.4)
Female 294 (53.6)
Smoking status Smoker 171 (31.2)
Former smoker 120 (21.9)
Non-smoker 257 (46.9)
Activity and revenue Without revenue 64 (11.7)
Replacement
revenue
44 (8.0)
Self-employed 19 (3.5)
Manual worker 112 (20.4)
Employee 101 (18.4)
Manager 10 (1.8)
Retired 198 (36.1)
Exposition to young children 285 (52.0)
Living conditions At home 530 (96.7)
Nursing home 15 (2.7)
Institution 3 (0.6)
Medical history
Influenza vaccination 18–49 years 18 (8.6)
50–64 years 45 (27.3)
≥65 years 93 (53.1)
Pneumococcal vaccination 18–49 years 6 (2.9)
50–64 years 10 (6.1)
≥65 years 48 (27.4)
Co-morbidities Asthma 64 (22.0)
Chronic bronchitis 61 (21.0)
Diabetes 45 (15.5)
Renal insufficiency 32 (11.0)
COPD 94 (32.3)
Cardiovascular
illness
96 (33.0)
Immunological
illness
15 (5.2)
Allergy to antibiotics 42 (7.7)
Clinical symptoms
Body temperature taken by
the physician (°C)
38.3 ± 0.9
Table 1 Demographics, medical history, clinical symptoms,
diagnostic tests, treatments and functional status of primary
care patients with a serious lower respiratory tract infection
(N = 548; Total cohort) (Continued)
Body temperature taken by
the patient (°C)
38.9 ± 0.5
Breaths per minute 21.7 ± 7.3
Systolic blood pressure (mmHg) 125.1 ± 17.1
Diastolic blood pressure
(mmHg)
76.7 ± 9.2
Cough 537 (98.0)
Sputum 428 (78.1)
Shortness of breath 362 (66.1)
Wheezing 239 (43.6)
Coryza 34 (6.2)
Breath sounds 443 (80.8)
Chest pain 310 (56.6)
Muscle ache 338 (61.7)
Headache 303 (55.3)
Disturbed sleep 303 (55.3)
Feeling unwell 459 (83.8)
Shivers 258 (47.1)
Interference with normal activity 374 (68.2)
Confusion/disorientation 48 (8.8)
Diarrhoea 66 (12.0)
CRB-65 score 0 (best health
status)
306 (55.8)
1 163 (29.7)
2 66 (12.0)
3 (worst health
status)
13 (2.4)
Diagnostic tests
X-ray radiography 50 (9.1)
X-ray signs No signs 15 (30.0)
Lobar
consolidation
9 (18.0)
Infiltrate 26 (52.0)
Pleural effusion 2 (4.0)
Blood culture 3 (0.5)
Tentative diagnosis Acute bronchitis 292 (53.3)
Bronchopneumonia 99 (18.1)
Pneumonia 76 (13.9)
COPD exacerbation 81 (14.8)
Treatment
Pharmacological treatment 540 (98.5)
Antibiotics 490 (90.7)
Antipyretics 425 (78.7)
NSAIDs 24 (4.4)
Flamaing et al. BMC Family Practice  (2015) 16:66 Page 4 of 10
Table 1 Demographics, medical history, clinical symptoms,
diagnostic tests, treatments and functional status of primary
care patients with a serious lower respiratory tract infection
(N = 548; Total cohort) (Continued)
Corticosteroids 91 (16.9)
Bronchodilators 135 (25.0)
Antitussives 259 (48.0)
Low weight
heparin
6 (1.1)
N-acetylcysteine 102 (18.9)
Non-pharmacological treatment 35 (6.4)
Oxygen 9 (25.7)
Physiotherapy 30 (85.7)
Sick leave 234 (42.7)
Supplementary home care 15 (2.7)
Hospitalisation 8 (1.5)
Functional status
EQ-5D index 0.61 ± 0.29
EQ-5D visual analogue scale
(mm)
51.7 ± 17.5
SD = Standard Deviation; COPD = Chronic Obstructive Pulmonary Disease;
°C = Celsius degree; mmHg =millimetre of mercury; CRB-65 = Confusion,
Respiratory rate, Blood Pressure and Age ≥65 years [16, 17]; NSAID =Non-Steroidal
Anti-Inflammatory Drug; EQ-5D index (http://www.euroqol.org/ and reference [18])
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nostic tests, treatments and functional status of the pa-
tients can be found in Table 1. Briefly, the 548 patients
(254 males [46.4 %] and 294 females [53.6 %]) were 54.8 ±
18.1 years old (18 to 93 years). An important proportion
of patients were retired (36.1 %). Half of the patients
(52 %) had regular contacts with young children. Current
smokers represented 31.2 % of patients. The vast majority
of patients lived at home (96.7 %). An influenza vaccine
had been administered to 28.5 % of patients and the 23-
pneumococcal polysaccharide vaccine (23-PPV) to 11.7 %
of patients. Overall, 53.1 % patients were suffering from
chronic diseases. An allergy to antibiotics was reported by
7.7 % of patients. The CRB-65 score was equal to 0 (best
health status) and 3 (worst health status) in 55.8 % and
2.4 % of patients, respectively. X-ray radiography was per-
formed in 9.1 % of patients. Pleural effusion was noted in
4.0 % of patients. A blood culture was performed in 3 pa-
tients. It was positive in only 1 patient and Streptococcus
pneumoniae was identified. The tentative diagnosis was
bronchopneumonia and pneumonia in 18.1 % and 13.9 %
of patients. A pharmacological treatment was prescribed
in the vast majority of patients (98.5 %). The antibiotic
treatment lasted for a mean of 8.3 ± 1.9 days (3 to
19 days). A non-pharmacological treatment was used in
6.4 % of patients. Sick leave lasted a mean of 5.6 ±
2.7 days (1 to 21 days). Supplementary home care was
needed in 2.7 % of patients and 1.5 % patients werereferred to the hospital. The mean EQ-5D score was
0.61 ± 0.29. The mean value reported for the VAS scale
was 51.7 ± 17.5 mm (midpoint between worst and best
possible health status).
Among the 85 patients participating in a complete
follow-up visit: 76.5 % had recovered, 18.8 % had im-
proved with residual symptoms, 1.2 % had no improve-
ment and 3.6 % had worsened symptoms. The mean
number of visits to the GPs was 1.62 ± 1.41. The number
of work days lost was 5.3 ± 7.1. The number of days pa-
tients needed external assistance was 3.5 ± 7.7.
Comparisons between non-pneumococcal (BinaxNOW-
negative) and pneumococcal (BinaxNOW-positive) SLRTIs
can be found in Table 2. In the BinaxNOW-positive pa-
tients, women were more numerous (p = 0.016), there was
less exposure to young children (p = 0.009), seasonal influ-
enza vaccination was less frequent (p = 0.037), COPD was
more frequent (p = 0.002), the body temperature measured
by the physician (p < 0.0001) and the number of breaths
per minute (p = 0.001) were higher, the systolic blood pres-
sure was lower (p < 0.0001), sputum was produced more
frequently (p = 0.026), the frequency of chest pain (p =
0.004), muscle ache (p = 0.040), confusion/disorientation
(p = 0.001) and diarrhoea (p < 0.0001) was higher, infiltrate
was more frequent (p = 0.030), pneumonia, bronchopneu-
monia and infectious exacerbations of COPD were more
frequent (p < 0.0001), non-pharmacological treatments
(physiotherapy) were more frequent (p = 0.018), EQ-5D
index (p < 0.0001) and VAS scale (p = 0.039) were lower,
translating a worse health status. All the other differences
between the two groups were not statistically significant
(p > 0.050).
In the follow-up cohort, the number of visits to the
GP (p = 0.001), the number of working days lost (p <
0.0001) and the number of days patients needed assist-
ance (p = 0.014) were higher in the BinaxNOW-positive
patients (Table 2).
In the total cohort, the proportion of pneumococcal
SLRTI was equal to 4.8 % (26 out of 544 cases; 95 % CI:
3.2 %–6.9 %).
The cross-table with the results of the BinaxNOW and
UAD assays can be found in Table 3. Eighty-eight poten-
tially contaminated samples had to be eliminated from
the UAD assay. There were no differences at baseline be-
tween the patients who had their sample eliminated and
those who were actually analysed (data not shown). Tak-
ing into account the positive samples from both Binax-
NOW and UAD assays, the proportion of pneumococcal
SLRTI among the SLRTI patients was equal to 4.8 % (22
out of 456 cases; 95 % CI: 3.1 %–7.2 %). Fifteen (15) of
these 22 positive cases (68.2 %) showed pneumococcal
serotypes represented in the PCV13. The number and
proportions of the different serotypes among the 15
UAD positive samples can be found in Table 4.
Table 2 Comparison of BinaxNOW-positive (pneumococcal) and -negative (non-pneumococcal) patients with serious lower respiratory
tract infection (Total and Follow-Up cohorts)
Categories Non-Pneumococcal SLRTI (N = 518) Pneumococcal SLRTI (N = 26) P value
Mean ± SD or N (%) Mean ± SD or N (%)
Total cohort
Demographics
Age 55.1 ± 18.1 52.2 ± 19.2 >0.050
Age group 18-49 years 195 (37.6) 11 (42.3) >0.050
50-64 years 157 (30.4) 6 (23.1)
≥65 years 166 (32.0) 9 (34.6)
Gender Male 246 (47.5) 6 (23.1) 0.016
Female 272 (52.5) 20 (76.9)
Smoking status Smoker 160 (30.9) 9 (34.6) >0.050
Former smoker 115 (22.2) 4 (15.4)
Non-smoker 243 (46.9) 13 (50.0
Activity and revenue Without revenue 57 (11.0) 5 (19.2) >0.050
Replacement revenue 40 (7.7) 4 (15.4)
Self-employed 18 (3.5) 1 (3.8)
Manual worker 106 (20.5) 6 (23.1)
Employee 99 (19.1) 1 (3.8)
Manager 9 (1.7) 0 (0.0)
Retired 189 (36.5) 9 (34.6)
Exposition to young children 277 (53.6) 7 (26.9) 0.009
Living conditions At home 500 (96.5) 26 (100.0) >0.050
Nursing home 15 (2.9) 0 (0.0)
Institution 3 (0.6) 0 (0.0)
Medical history
Influenza vaccination 141 (27.2) 2 (7.7) 0.037
Pneumococcal vaccination 60 (11.6) 4 (15.4) >0.050
Co-morbidities Asthma 57 (11.0) 6 (23.1) >0.050
Chronic bronchitis 55 (10.6) 6 (23.1) >0.050
Diabetes 42 (8.1) 3 (11.5) >0.050
Renal insufficiency 28 (5.4) 4 (15.4) >0.050
COPD 83 (16.0) 11 (42.3) 0.002
Cardiovascular illness 92 (17.8) 4 (15.4) >0.050
Immunological illness 6 (1.2) 1 (3.8) >0.050
Allergy to antibiotics 41 (7.9) 1 (3.8) >0.050
Clinical symptoms
Body temperature taken by the physician (°C) 38.2 ± 0.9 38.9 ± 0.6 <0.0001
Body temperature taken by the patient (°C) 38.9 ± 0.5 39.0 ± 0.1 >0.050
Breaths per minute 21.5 ± 7.2 27.1 ± 6.2 0.001
Systolic blood pressure (mmHg) 128 ± 57 111 ± 18 <0.0001
Diastolic blood pressure 77 ± 9.2 74 ± 9.1 >0.050
Cough 507 (97.9) 26 (100.0) >0.050
Sputum 399 (77.0) 25 (96.2) 0.026
Shortness of breath 341 (65.8) 19 (73.1) >0.050
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Table 2 Comparison of BinaxNOW-positive (pneumococcal) and -negative (non-pneumococcal) patients with serious lower respiratory
tract infection (Total and Follow-Up cohorts) (Continued)
Wheezing 227 (43.8) 10 (38.5) >0.050
Coryza 34 (6.6) 0 (0.0) >0.050
Breath sounds 417 (80.5) 22 (84.6) >0.050
Chest pain 286 (55.2) 22 (84.6) 0.004
Muscle ache 314 (60.6) 21 (80.8) 0.040
Headache 282 (54.4) 18 (69.2) >0.050
Disturbed sleep 284 (54.8) 17 (65.4) >0.050
Feeling unwell 433 (83.6) 23 (88.5) >0.050
Shivers 241 (46.5) 16 (61.5) >0.050
Interference with normal activity 351 (67.8) 21 (80.8) >0.050
Confusion/disorientation 40 (7.7) 8 (30.8) 0.001
Diarrhoea 55 (10.6) 11 (42.3) <0.0001
CRB-65 score 0 (best) 292 (56.4) 11 (42.3) >0.050
1 156 (30.1) 6 (23.1)
2 61 (11.8) 5 (19.2)
3 (worst) 9 (1.7) 4 (15.4)
Diagnostic tests
X-ray radiography 44 (8.5) 5 (19.2) >0.050
X-ray signs No signs 9 (1.7) 0 (0.0) >0.050
Lobar consolidation 7 (1.4) 2 (7.7) >0.050
Infiltrate 22 (4.2) 4 (15.4) 0.030
Pleural effusion 2 (7.4) 0 (0.0) >0.050
Blood culture 2 (0.4) 1 (3.8) >0.050
Tentative diagnosis Acute bronchitis 288 (55.6) 1 (3.8) <0.0001
Bronchopneumonia 87 (16.8) 11 (42.3)
Pneumonia 70 (13.5) 6 (23.1)
COPD exacerbation 73 (14.1) 8 (30.8)
Treatment
Pharmacological treatment 511 (98.6) 25 (96.2) >0.050
Antibiotics 462 (89.2) 24 (92.3) >0.050
Antipyretics 405 (78.2) 18 (69.2) >0.050
NSAIDs 23 (4.4) 1 (3.8) >0.050
Corticosteroids 83 (16.0) 7 (26.9) >0.050
Bronchodilators 130 (25.1) 5 (19.2) >0.050
Antitussives 240 (46.3) 17 (65.4) >0.050
Low weight heparin 5 (1.0) 1 (3.8) >0.050
N-acetylcysteine 98 (18.9) 2 (7.7) >0.050
Non-pharmacological treatment 29 (5.6) 5 (19.2) 0.018
Oxygen 8 (1.5) 1 (3.8) >0.050
Physiotherapy 25 (4.8) 5 (19.2) 0.010
Sick leave 220 (42.5) 11 (42.3) >0.050
Supplementary home care 14 (2.7) 1 (3.8) >0.050
Hospitalisation 6 (1.2) 2 (7.7) >0.050
Functional status
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Table 2 Comparison of BinaxNOW-positive (pneumococcal) and -negative (non-pneumococcal) patients with serious lower respiratory
tract infection (Total and Follow-Up cohorts) (Continued)
EQ-5D index 0.62 ± 0.28 0.35 ± 0.35 <0.0001
EQ-5D visual analogue scale (mm) 52 ± 17 44 ± 22 0.039
Follow-up cohort
Visits to GPs 1.27 ± 1.30 2.44 ± 1.36 0.001
Working days lost 3.49 ± 4.83 9.56 ± 9.46 <0.0001
Number of days patients needed assistance 2.14 ± 6.34 6.64 ± 9.70 0.014
SD = Standard Deviation; COPD = Chronic Obstructive Pulmonary Disease; °C = Celsius degree; mmHg =millimetre of mercury; CRB-65 = Confusion, Respiratory rate,
Blood Pressure and Age ≥65 years [16, 17]; NSAID = Non-Steroidal Anti-Inflammatory Drug; EQ-5D index (http://www.euroqol.org/ and reference [18]); GP = General
Practitioner; P value = statistical probability of Mann-Whitney, Chi-square or Fisher’s exact tests as appropriate. Statistical significance for p values <0.00075 (Bonferroni’s
correction for the multiplicity of analyses)
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This study contributes to the knowledge of pneumococ-
cal LRTIs in primary care in Europe and particularly in
Belgium. Indeed, most data are generated on pneumo-
coccal invasive disease in hospital settings, where culture
methods to identify the pathogens are available. This is
also one of the rare studies to combine BinaxNOW® S.
pneumoniae and UAD assays for the identification of
pneumococcal antigens in urine samples. It confirmed, in
agreement with previous studies [10, 13], that rapid urine
antigen assays (in clinical routine practice the BinaxNOW
test would take around 15 min to obtain the results) can
determine SLRTI aetiology in adults and quickly identify a
group of patients in whom antibiotic treatment should be
considered.
The proportion (4.8 %) of pneumococcal infections
among primary care patients diagnosed with a SLRTI
was globally in agreement with the previous epidemio-
logical studies [21, 22].
The burden of SLRTIs and particularly of pneumococ-
cal SLRTIs has been highlighted in many other studies
[7, 8, 21, 23] and is confirmed by the current study. The
proportion of European patients consulting in primary
care with LRTI, which receives antibiotics, ranges from
27 % in the Netherlands to 75 % in the United Kingdom
[15, 16]. In our study, the percentage of antibiotic pre-
scription was around 90 %. This could be due to the fact
that our patients presented with SLRTIs, were quite
old (55 years in average) and appeared to have severe
comorbidities: 32 % had a COPD, 33 % had a cardio-
vascular disease and 15.5 % had diabetes.Table 3 Cross-table of the results of the BinaxNOW and Urine Antig
Urine Antigen Detection Assay Negative N(%)
Positive N(%)
Total N (%)
*: 88 contaminated samples were eliminated from the analysisThe comorbidity profile of our patients was in agree-
ment with the one published by Torres et al. [1]: 9.4–
62 % COPD, 3–50 % asthma, 10–47.2 % chronic heart
disease, 4.9–33 % diabetes and 0.5–26.7 % chronic renal
diseases. In the study of Ryan et al. [24], elderly patients
with COPD had nearly six-times the incidence of pneu-
monia compared with those without COPD.
The CRB-65 score was the worst (level 2 or 3) in
34.6 % of patients with a pneumococcal versus 13.5 % of
patients with a non-pneumococcal SLRTI. Although not
statistically significant, this difference is important since
a higher CRB-65 score also correlates with pneumonia
severity and the risk of death [19].
Social-economic deprivation is considered as a risk
factor for invasive pneumococcal disease [25] and for
CAP [26]. The same tendency was observed in our
study, 34.6 % of patients with a pneumococcal disease
being without revenue or with replacement revenue.
Although not statistically significantly different, this was
almost twice the percentage of patients without a pneumo-
coccal disease (18.7 %). All patients are not equal when fa-
cing SLRTIs and economic deprivation is a parameter that
should be taken into account when considering the pre-
scription of antibiotics and vaccination coverage.
In terms of clinical symptoms potentially differentiat-
ing a bacterial from a viral LRTI, fever, headache, the ab-
sence of diarrhoea and the presence of an infiltrate at
the X-ray radiography predict a bacterial aetiology [5].
This was confirmed in our study for the presence of an
infiltrate at the X-ray radiography but not for diarrhoea.
The tentative diagnosis of pneumonia was more frequenten Detection assays*
BinaxNOW assay Total N(%)
Negative N(%) Positive N(%)
434 (95.2) 7 (1.5) 441 (96.7)
10 (2.2) 5 (1.1) 15 (3.3)
444 (97.4) 12 (2.6) 456 (100.0)
Table 4 Number and proportion of the serotypes in
pneumococcal serious lower respiratory tract infections using
the Urine Antigen Detection (UAD) assay
Pneumococcal serotype N %
1 1 6.67
3 1 6.67
5 1 6.67
6A 2 13.33
7 F 2 13.33
14 2 13.33
18C 1 6.67
19A 5 33.33
Total* 15 100.0
*15 (3.3 %) out of 456 SLRTI cases were positive for the UAD assay
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in our study (65 % versus 30 %) and in the study of
Holm et al. [7] (33 % versus 17 %).
The CAPiTA trial has demonstrated 45.6 % efficacy of
PCV13 against vaccine-type pneumococcal pneumonia,
45.0 % efficacy against vaccine-type non-bacteremic
pneumococcal pneumonia and 75.0 % efficacy against
vaccine-type invasive pneumococcal disease among adults
aged ≥65 years [14, 27]. In our study, 68 % of serotypes
causing pneumococcal SLRTI were potentially pre-
ventable by the PCV13. On August 13, 2014, the ACIP
recommended routine use of PCV13 among adults
aged ≥65 years. PCV13 should be administered in series
with the 23-PPV, the vaccine currently recommended
for adults aged ≥65 years [27].
The limitations of the current study are intrinsic to its
observational, epidemiological and real-life design. All
general practitioners of the study could freely prescribe
the examinations, laboratory analyses and treatments,
they considered clinically relevant and practical. In clin-
ical primary care in Belgium, GPs do not routinely refer
patients for a chest X-ray in case of SLRTI. Moreover,
the results of radiography are sometimes available only
after a few days. This explains the low uptake of chest
radiography (50 patients [9.1 %]). The collection of a
urine sample for the BinaxNOW was the only interven-
tion required by the protocol. To avoid any influence of
the result of the test on patient’s follow-up, all urine ana-
lyses were performed by a central laboratory and the
physicians remained blinded to its results in the setting
of our study. The investigators were not able to enrol
670 patients and the observed frequency of pneumococ-
cal infection being significantly lower than the forecasted
8.5 %, it was not possible to reach 50 BinaxNOW-positive
patients. Eighty-eight samples were contaminated and were
therefore discarded from the UAD assay. Limitations are
also inherent to the sensitivity and specificity of the assays.
Non-PCV13 serotypes are not identified by the UAD assay.The multiplicity of statistical inferential tests was taken
into account. P values lower than 0.00075 have to be
considered statistically significant but higher values
should be considered indicative only and should be
interpreted cautiously. Moreover, the results should not
be extrapolated to other populations or other time pe-
riods without caution.Conclusions
In this study, Streptococcus pneumoniae was responsible
for approximately 5 % of SLRTIs observed in primary
care in Belgium. Pneumococcal infections were associ-
ated with clinically and statistically significant increases
of morbidity. Sixty-eight percent (68 %) of serotypes caus-
ing SLRTI were potentially preventable by the PCV13.
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